Search company, investor...



Angel | Alive

About SpheriTech

Spherotech was established in 1992 to manufacture and supply uniform microparticles for biomedical and diagnostic applications. Our team supplies scientists with high quality latex, fluorescent, paramagnetic, ferromagnetic and various colored microparticles. The surface chemistry of the microspheres can be modified with functional groups to suit various applications. We also manufacture coated particles with antibodies or ligands such as avidin, streptavidin and biotin for immunological applications.

Headquarters Location

1840 Industrial Drive

Libertyville, Illinois, 60048,

United States


SpheriTech's Product Videos

Compete with SpheriTech?

Ensure that your company and products are accurately represented on our platform.

SpheriTech's Products & Differentiators


    Rainbow Calibration Particles, 8 peaks, 1E7/mL, 3.0-3.4 um, 5 mL

Expert Collections containing SpheriTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SpheriTech is included in 1 Expert Collection, including Advanced Materials.


Advanced Materials

1,275 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

SpheriTech Patents

SpheriTech has filed 8 patents.

The 3 most popular patent topics include:

  • Proteinogenic amino acids
  • Blood
  • Cosmetics
patents chart

Application Date

Grant Date


Related Topics




Transfusion medicine, Hematology, Paragliders, Blood, Proteinogenic amino acids


Application Date


Grant Date



Related Topics

Transfusion medicine, Hematology, Paragliders, Blood, Proteinogenic amino acids



Latest SpheriTech News

Regenerative Medicine in Action

Aug 19, 2018

13:09 EDT 19 Aug 2018 | BioNow Science firm at The Heath Business and Technical Park awarded grant to fund cutting-edge research that will revolutionize hip - joint operationsSpheriTech, a leading life science company based at The Heath Business and Technical Park in Runcorn, has been awarded a £174k grant towards pioneering work to develop technology that will revolutionise the way physicians repair joints, with a particular focus on repair of hip lesions.SpheriTech are responsible for the laboratory-based polymer development for the new treatment; JRI Orthopaedics are developing surgical instruments to deliver the technique while Cambridge University will undertake the clinical trials. The total project cost across the three partners is £781k of which £545k will be funded by the UK’s innovation agency, Innovate UK. Each year around 180,000 patients have total hip or knee replacements in the UK. Don Wellings, founder and CEO of SpheriTech, says polymers that he and his team are developing have the potential to revolutionize regenerative medicine, including treatment for joint degeneration. The company are already making great strides on spinal cord repair and skin healing.“We believe the new techniques we are developing could ultimately delay hip and other joint replacement operations and potentially make them obsolete in the coming years,” says Dr Wellings.He adds: “Treatment to hips is required when the cartilage in the joint disintegrates, eventually causing bone to rub on bone, making it painful to walk. We are developing a polymer that surgeons can insert into the hip joint which will regenerate the cartilage and the underlying bone. It means that if the joint deterioration can be caught early enough, using key-hole surgery techniques, surgeons will be able to take away the damaged tissue and replace it with SpheriTech’s polymer. “The amount of cartilage that generally needs replacing measures about 1-2cm in diameter. SpheriTech polymer, Proliferate® will be inserted into the joint through a tube, with surgeons using cameras to guide the delivery of the polymer to the prepared site. It will then regenerate the cartilage and underlying bone thus repairing the joint and avoiding the need for an intrusive and major hip-replacement operation.”Dr Wellings says the Innovate UK funding will help fund two years of further research to develop and fine-tune the polymer and delivery technique which will be followed up by clinical studies. He believes the polymer technology will trigger repair of the hip joint within weeks.“This will revolutionize hip treatments – reducing costs to the health care industry, making treatment speedier and safer for patients, reducing post-operative care and the expense of physiotherapy. Potentially this new form of treatment could, in the longer term, minimize the need for total hip replacements altogether.” Dr Wellings adds: “The current trials are focused on hip joints but this technique can be adapted to treat knee, shoulder and elbow joints. Our polymers can also regenerate bone and we are researching how they can be introduced for the treatment of trauma injury which would also revolutionize the way surgeons treat major bone injury.”SpheriTech is also working on a project to develop synthetic blood by effectively producing artificial red blood cells. This new ‘blood substitute’, SpheriSome® Hb, could ultimately end the necessity for the blood donors’ programme. Related Biotechnology, Pharmaceutical and Healthcare News

SpheriTech Frequently Asked Questions (FAQ)

  • Where is SpheriTech's headquarters?

    SpheriTech's headquarters is located at 1840 Industrial Drive, Libertyville.

  • What is SpheriTech's latest funding round?

    SpheriTech's latest funding round is Angel.

  • What products does SpheriTech offer?

    SpheriTech's products include RCP-30-5A and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.